scholarly journals Menopausal hormone therapy use and risk of primary liver cancer in the clinical practice research datalink

2015 ◽  
Vol 138 (9) ◽  
pp. 2146-2153 ◽  
Author(s):  
Katherine A. McGlynn ◽  
Katrina Hagberg ◽  
Jie Chen ◽  
Megan Braunlin ◽  
Barry I. Graubard ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Cancer ◽  
Hormone Therapy ◽  
Primary Liver Cancer ◽  
Menopausal Hormone Therapy ◽  
Practice Research ◽  
Clinical Practice Research Datalink

scholarly journals Domperidone use and risk of primary liver cancer in the Clinical Practice Research Datalink

2018 ◽  
Vol 55 ◽  
pp. 170-175
Author(s):  
Jake E. Thistle ◽  
Jessica L. Petrick ◽  
Baiyu Yang ◽  
Marie C. Bradley ◽  
Barry I. Graubard ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Practice Research ◽  
Clinical Practice Research Datalink

scholarly journals Associations of NSAID and paracetamol use with risk of primary liver cancer in the Clinical Practice Research Datalink

2016 ◽  
Vol 43 ◽  
pp. 105-111 ◽  
Author(s):  
Baiyu Yang ◽  
Jessica L. Petrick ◽  
Jie Chen ◽  
Katrina Wilcox Hagberg ◽  
Vikrant V. Sahasrabuddhe ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Practice Research ◽  
Clinical Practice Research Datalink

scholarly journals Associations of antibiotic use with risk of primary liver cancer in the Clinical Practice Research Datalink

2016 ◽  
Vol 115 (1) ◽  
pp. 85-89 ◽  
Author(s):  
Baiyu Yang ◽  
Katrina Wilcox Hagberg ◽  
Jie Chen ◽  
Vikrant V Sahasrabuddhe ◽  
Barry I Graubard ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Antibiotic Use ◽  
Practice Research ◽  
Clinical Practice Research Datalink

scholarly journals Statin Use and Risk of Primary Liver Cancer in the Clinical Practice Research Datalink

2015 ◽  
Vol 107 (4) ◽  
pp. djv009-djv009 ◽  
Author(s):  
K. A. McGlynn ◽  
K. Hagberg ◽  
J. Chen ◽  
B. I. Graubard ◽  
W. T. London ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Liver Cancer ◽  
Primary Liver Cancer ◽  
Practice Research ◽  
Clinical Practice Research Datalink ◽  
Statin Use

Heterogeneity between Pharmacoepidemiological Studies Using the Clinical Practice Research Datalink (CPRD)

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1507-P
Author(s):  
ALICE KOECHLIN ◽  
PETER BOYLE ◽  
PHILIPPE AUTIER
Keyword(s):  
Clinical Practice ◽  
Practice Research ◽  
Clinical Practice Research Datalink

scholarly journals AB0576 BONE EROSION IN PSORIATIC ARTHRITIS ASSOCIATED WITH PSORIASIS DURATION, SKIN, NAIL AND JOINT DISEASE SEVERITY

2021 ◽  
Vol 80 (Suppl 1) ◽  
pp. 1325.2-1326
Author(s):  
M. Chamurlieva ◽  
E. Loginova ◽  
T. Korotaeva ◽  
Y. Korsakova ◽  
E. Gubar ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Psoriatic Arthritis ◽  
Disease Severity ◽  
Bone Erosion ◽  
Joint Disease ◽  
Practice Research ◽  
Forest Plot ◽  
Clinical Practice Research Datalink ◽  
Increased Risk ◽  
Nail Disease

Background:Psoriatic arthritis (PsA) is heterogeneous in its clinical presentation and disease course, but many patients (pts) develop a destructive form of arthritis. Psoriasis (PsO) precedes arthritis by an average of 7 years. [1]. Theory of transition from PsO to PsA has been proposed recently [2]. But association between skin disease severity and joint disease are still unclear.Objectives:to evaluate association between bone erosion, PsO duration, skin and nail disease severity in PsA pts based on data from clinical practice (RU-PsART cohort).Methods:737 (M/F=350/387) PsA pts fulfilling the CASPAR criteria were included. Mean age 47.4±12.7 years (yrs), PsA duration 55[17;120] mos., PsO duration 165[74.5;292] mos., mean DAPSA 23.3[14;36.9] mos., HAQ-DI - 0.98 [0.5;1.38], CRP - 7.4 [2.1;18] mg/l. All pts underwent standard clinical examination (tender joins count (TJC)/68, swelling joints count (SJC)/66, CRP (mg/l), DAPSA, dactylitis, enthesitis by LEI + Plantar Facia (PF), HAQ-DI. Mild disease was defined as body surface area (BSA)≤10%, moderate to severe as BSA>10%. The presence/absent of nail PsO was evaluated. X-ray of feet and hand were done in 622 out of 737 pts. The one-factor model of logistic regression was used to identify a group of features that are associated with achievement MDA. M±SD, Me [Q25; Q75], Min-Max, %, t-test, Pierson-χ2, Manna-Whitney tests, ORs with 95% CI were performed. All p<0.05 were considered to indicate statistical significance.Results:PsO precedes of PsA by an average of 9.2 years. BSA≤10% was found in 615 out of 672 pts (91.5%), BSA>10% - in 57 out of 672 pts (8.5%). Nail PsO were seen in 230 out of 737 (31.2%). Bone erosion was found in 237 out of 622 of pts (38.1%). Among these pts nail PsO were seen in 67 out of 237 pts (28.3%). Enthesitis found in 236 out of 737 pts (42.1%), dactylitis – in 197 out 731 pts (27%), axial PsA – in 315 out of 731 pts (43.1%). Bone erosion significantly associated with PsO duration more than 5 yrs., skin and nail PsO severity, high PsA activity by DAPSA, axial manifestation and duration of PsA > 36 mos. (Figure 1).Figure 1Forest plot of factors associated with bone erosion in PsA pts.Conclusion:In our cohort the majority of PsA pts had mild PsO preceded PsA on average of 9.2 yrs. Bone erosion was found in 30% of PsA pts which associated with PsO duration, skin and nail disease severity as well as with PsA activity. Early diagnosis and therapeutic intervention within a “window of opportunity” are very important for improving outcomes and prevent structural damage in PsA.References:[1]Tillett W, et al. Interval between onset of psoriasis and psoriatic arthritis comparing the UK Clinical Practice Research Datalink with a hospital-based cohort. Rheumatol. 2017; 56, 2109–2113[2]Scher JU, et al. Preventing psoriatic arthritis: focusing on patients with psoriasis at increased risk of transition. Nat Rev Rheumatol. 2019;15(3):153-166. doi: 10.1038/s41584-019-0175-0. PMID: 30742092.Disclosure of Interests:None declared.

scholarly journals Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD)

2021 ◽  
Author(s):  
Toby J L Humphrey ◽  
Glen James ◽  
Eric T Wittbrodt ◽  
Donna Zarzuela ◽  
Thomas F Hiemstra
Keyword(s):  
Heart Failure ◽  
Acute Kidney Injury ◽  
Clinical Practice ◽  
Clinical Outcomes ◽  
Kidney Injury ◽  
Practice Research ◽  
Clinical Practice Research Datalink ◽  
Ckd Stage ◽  
First Occurrence ◽  
Baseline Characteristics

Abstract Background Users of guideline-recommended renin–angiotensin–aldosterone system (RAAS) inhibitors may experience disruptions to their treatment, e.g. due to hyperkalaemia, hypotension or acute kidney injury. The risks associated with treatment disruption have not been comprehensively assessed; therefore, we evaluated the risk of adverse clinical outcomes in RAAS inhibitor users experiencing treatment disruptions in a large population-wide database. Methods This exploratory, retrospective analysis utilized data from the UK’s Clinical Practice Research Datalink, linked to Hospital Episodes Statistics and the Office for National Statistics databases. Adults (≥18 years) with first RAAS inhibitor use (defined as angiotensin-converting enzyme inhibitors or angiotensin receptor blockers) between 1 January 2009 and 31 December 2014 were eligible for inclusion. Time to the first occurrence of adverse clinical outcomes [all-cause mortality, all-cause hospitalization, cardiac arrhythmia, heart failure hospitalization, cardiac arrest, advancement in chronic kidney disease (CKD) stage and acute kidney injury] was compared between RAAS inhibitor users with and without interruptions or cessations to treatment during follow-up. Associations between baseline characteristics and adverse clinical outcomes were also assessed. Results Among 434 027 RAAS inhibitor users, the risk of the first occurrence of all clinical outcomes, except advancement in CKD stage, was 8–75% lower in patients without interruptions or cessations versus patients with interruptions/cessations. Baseline characteristics independently associated with increased risk of clinical outcomes included increasing age, smoking, CKD, diabetes and heart failure. Conclusions These findings highlight the need for effective management of factors associated with RAAS inhibitor interruptions or cessations in patients for whom guideline-recommended RAAS inhibitor treatment is indicated.

Sign in / Sign up

Export Citation Format

Share Document